Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals - NEC
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:CORT
- CUSIP: 21835210
- Web: www.corcept.com
Capitalization:- Market Cap: $1.38 billion
- Outstanding Shares: 113,187,000
Average Prices:- 50 Day Moving Avg: $11.92
- 200 Day Moving Avg: $10.16
- 52 Week Range: $5.24 - $13.25
P/E:- Trailing P/E Ratio: 113.21
- Foreward P/E Ratio: 23.46
- P/E Growth: 0.92
Sales & Book Value:- Annual Revenue: $92.86 million
- Price / Sales: 14.87
- Book Value: $0.44 per share
- Price / Book: 27.73
Profitability:- EBIDTA: $14.4 million
- Net Margins: 13.51%
- Return on Equity: 33.97%
- Return on Assets: 19.04%
Debt:- Current Ratio: 2.59%
- Quick Ratio: 2.48%
Misc:- Average Volume: 980,678 shs.
- Beta: 2.05
- Short Ratio: 7.42
Frequently Asked Questions for Corcept Therapeutics Incorporated (NASDAQ:CORT)
What is Corcept Therapeutics Incorporated's stock symbol?
Corcept Therapeutics Incorporated trades on the NASDAQ under the ticker symbol "CORT."
How were Corcept Therapeutics Incorporated's earnings last quarter?
Corcept Therapeutics Incorporated (NASDAQ:CORT) released its quarterly earnings data on Monday, May, 1st. The company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.03 by $0.01. The company earned $27.60 million during the quarter, compared to the consensus estimate of $25.53 million. Corcept Therapeutics Incorporated had a return on equity of 33.97% and a net margin of 13.51%. The business's revenue was up 71.9% on a year-over-year basis. View Corcept Therapeutics Incorporated's Earnings History.
When will Corcept Therapeutics Incorporated make its next earnings announcement?
Where is Corcept Therapeutics Incorporated's stock going? Where will Corcept Therapeutics Incorporated's stock price be in 2017?
4 brokerages have issued 12 month price targets for Corcept Therapeutics Incorporated's shares. Their predictions range from $7.00 to $20.00. On average, they anticipate Corcept Therapeutics Incorporated's stock price to reach $14.25 in the next twelve months. View Analyst Ratings for Corcept Therapeutics Incorporated.
Who are some of Corcept Therapeutics Incorporated's key competitors?
Some companies that are related to Corcept Therapeutics Incorporated include BTG plc (BTG), Horizon Pharma PLC (HZNP), Amicus Therapeutics (FOLD), Cambrex Corporation (CBM), Theravance Biopharma (TBPH), Pacira Pharmaceuticals (PCRX), Innoviva (INVA), Impax Laboratories (IPXL), Amphastar Pharmaceuticals (AMPH), Lannett Co (LCI), AMAG Pharmaceuticals (AMAG), SciClone Pharmaceuticals (SCLN), Aceto Corporation (ACET), Teligent (TLGT), Collegium Pharmaceutical (COLL), Aquinox Pharmaceuticals (AQXP), Tetraphase Pharmaceuticals (TTPH) and Corium International (CORI).
Who are Corcept Therapeutics Incorporated's key executives?
Corcept Therapeutics Incorporated's management team includes the folowing people:
- James N. Wilson, Chairman of the Board
- Joseph K. Belanoff M.D., President, Chief Executive Officer, Director
- Gary Charles Robb, Chief Financial Officer, Chief Accounting Officer, Secretary
- Renee D. Gala, Director
- Len L. Baker Jr., Independent Director
- Daniel Bradbury, Independent Director
- Joseph C. Cook Jr., Independent Director
- Patrick G. Enright, Independent Director
Who owns Corcept Therapeutics Incorporated stock?
Corcept Therapeutics Incorporated's stock is owned by a number of of retail and institutional investors. Top institutional investors include
LONGITUDE CAPITAL PARTNERS, LLC
(2.10%), Acadian Asset Management LLC (1.50%), Russell Investments Group Ltd. (0.54%), Capital Impact Advisors LLC (0.07%), Strs Ohio (0.06%) and Sit Investment Associates Inc. (0.06%). Company insiders that own Corcept Therapeutics Incorporated stock include Daniel Bradbury, David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, James N Wilson, Joseph K Belanoff, Patrick G Enright and Steven Lo. View Institutional Ownership Trends for Corcept Therapeutics Incorporated.
Who sold Corcept Therapeutics Incorporated stock? Who is selling Corcept Therapeutics Incorporated stock?
Corcept Therapeutics Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Capital Impact Advisors LLC and Campbell & CO Investment Adviser LLC. Company insiders that have sold Corcept Therapeutics Incorporated stock in the last year include David L Mahoney, James N Wilson, Joseph K Belanoff and Patrick G Enright. View Insider Buying and Selling for Corcept Therapeutics Incorporated.
Who bought Corcept Therapeutics Incorporated stock? Who is buying Corcept Therapeutics Incorporated stock?
Corcept Therapeutics Incorporated's stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Russell Investments Group Ltd., Sit Investment Associates Inc., Eidelman Virant Capital, Sheets Smith Wealth Management, Bank of Montreal Can and Strs Ohio. Company insiders that have bought Corcept Therapeutics Incorporated stock in the last two years include G Leonard Baker Jr and Gary Charles Robb. View Insider Buying and Selling for Corcept Therapeutics Incorporated.
How do I buy Corcept Therapeutics Incorporated stock?
Shares of Corcept Therapeutics Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corcept Therapeutics Incorporated's stock price today?
One share of Corcept Therapeutics Incorporated stock can currently be purchased for approximately $12.20.
MarketBeat Community Rating for Corcept Therapeutics Incorporated (NASDAQ CORT)MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Corcept Therapeutics Incorporated (NASDAQ:CORT) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $14.25 (16.80% upside) |
Analysts' Ratings History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/18/2017 | Ladenburg Thalmann Financial Services | Set Price Target | Buy | $15.00 -> $20.00 | Low |  |
| 5/15/2017 | Piper Jaffray Companies | Set Price Target | Buy | $18.00 | Low | |
| 12/20/2016 | Janney Montgomery Scott | Initiated Coverage | Sell | $7.00 | N/A | |
| 11/2/2016 | FBR & Co | Set Price Target | Buy | $12.00 | N/A | |
(Data available from 7/26/2015 forward)
Earnings History for Corcept Therapeutics Incorporated (NASDAQ:CORT)Earnings History by Quarter for Corcept Therapeutics Incorporated (NASDAQ CORT)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/31/2017 | | $0.07 | | | | | N/A | |
| 5/1/2017 | Q1 2017 | $0.03 | $0.04 | $25.53 million | $27.60 million | View | Listen | |
| 3/6/2017 | Q4 2016 | $0.04 | $0.04 | $23.85 million | $23.81 million | View | N/A | |
| 11/1/2016 | Q316 | $0.01 | $0.02 | $21.24 million | $21.70 million | View | N/A | |
| 1/28/2016 | Q415 | ($0.02) | $0.01 | $15.50 million | $15.00 million | View | N/A | |
| 11/5/2015 | Q315 | ($0.02) | ($0.01) | $13.90 million | $13.30 million | View | N/A | |
| 8/5/2015 | Q215 | ($0.04) | ($0.02) | $11.67 million | $11.96 million | View | N/A | |
| 5/7/2015 | Q115 | ($0.04) | ($0.05) | $10.50 million | $10.10 million | View | N/A | |
| 3/4/2015 | Q414 | ($0.06) | ($0.03) | $9.10 million | $9.01 million | View | N/A | |
| 11/4/2014 | Q214 | ($0.07) | ($0.05) | $7.62 million | $7.28 million | View | N/A | |
| 5/7/2014 | Q114 | ($0.10) | ($0.13) | $5.01 million | $4.41 million | View | N/A | |
| 3/5/2014 | Q413 | ($0.10) | ($0.11) | $4.01 million | $4.10 million | View | N/A | |
| 1/30/2014 | Q4 | ($0.12) | ($0.10) | | | View | N/A | |
| 11/7/2013 | Q313 | ($0.12) | ($0.08) | $2.70 million | $2.60 million | View | N/A | |
| 8/8/2013 | Q2 2013 | ($0.11) | ($0.10) | $2.72 million | $1.90 million | View | N/A | |
| 5/2/2013 | Q1 2013 | ($0.09) | ($0.10) | $2.48 million | $1.72 million | View | N/A | |
| 3/7/2013 | Q4 2012 | ($0.09) | ($0.09) | $1.50 million | $1.38 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT)Current Year EPS Consensus Estimate: $0.26 EPS
Next Year EPS Consensus Estimate: $0.52 EPS
Dividend History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Corcept Therapeutics Incorporated (NASDAQ:CORT)Insider Ownership Percentage: 19.20%
Institutional Ownership Percentage: 53.49%
Insider Trades by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/19/2017 | David L Mahoney | Director | Sell | 23,006 | $12.50 | $287,575.00 | |
| 7/18/2017 | David L Mahoney | Director | Sell | 6,091 | $12.50 | $76,137.50 | |
| 7/13/2017 | David L Mahoney | Director | Sell | 6,994 | $12.50 | $87,425.00 | |
| 7/12/2017 | David L Mahoney | Director | Sell | 6,510 | $12.50 | $81,375.00 | |
| 5/4/2017 | Gary Charles Robb | CFO | Buy | 5,600 | $9.75 | $54,600.00 | |
| 3/16/2017 | Patrick G. Enright | Director | Sell | 269,955 | $9.94 | $2,683,352.70 | |
| 3/15/2017 | Patrick G Enright | Director | Sell | 600,000 | $10.15 | $6,090,000.00 | |
| 3/8/2017 | Patrick G Enright | Director | Sell | 750,000 | $9.75 | $7,312,500.00 | |
| 2/27/2017 | Patrick G Enright | Director | Sell | 2,500,000 | $8.81 | $22,025,000.00 | |
| 11/25/2016 | Patrick G Enright | Director | Sell | 36,941 | $9.34 | $345,028.94 | |
| 11/21/2016 | Patrick G Enright | Director | Sell | 544,100 | $9.56 | $5,201,596.00 | |
| 11/16/2016 | Patrick G Enright | Director | Sell | 174,847 | $9.55 | $1,669,788.85 | |
| 11/11/2016 | James N Wilson | Director | Sell | 158,812 | $8.51 | $1,351,490.12 | |
| 11/11/2016 | Joseph K Belanoff | Insider | Sell | 500,000 | $8.98 | $4,490,000.00 | |
| 11/7/2016 | Joseph K Belanoff | CEO | Sell | 500,000 | $8.31 | $4,155,000.00 | |
| 5/10/2016 | G Leonard Baker Jr | Director | Buy | 100,000 | $4.88 | $488,000.00 | |
| 1/6/2016 | James N Wilson | Director | Sell | 1,188 | $4.90 | $5,821.20 | |
| 12/10/2015 | Daniel Bradbury | Director | Sell | 20,000 | $4.85 | $97,000.00 | |
| 11/24/2015 | Daniel Bradbury | Director | Sell | 40,000 | $5.00 | $200,000.00 | |
| 11/12/2015 | James N Wilson | Director | Sell | 20,000 | $4.90 | $98,000.00 | |
| 11/2/2015 | Steven Lo | VP | Sell | 12,500 | $4.00 | $50,000.00 | |
| 10/13/2015 | Steven Lo | VP | Sell | 53,033 | $3.82 | $202,586.06 | |
| 10/7/2015 | Steven Lo | VP | Sell | 5,300 | $4.00 | $21,200.00 | |
| 10/6/2015 | Steven Lo | VP | Sell | 50,000 | $3.76 | $188,000.00 | |
| 9/16/2015 | Daniel Bradbury | Director | Sell | 20,000 | $4.96 | $99,200.00 | |
| 9/1/2015 | James N Wilson | Director | Sell | 10,000 | $4.90 | $49,000.00 | |
| 8/27/2015 | Daniel Bradbury | Director | Sell | 20,000 | $4.76 | $95,200.00 | |
| 7/21/2015 | Daniel Bradbury | Director | Sell | 10,000 | $4.98 | $49,800.00 | |
| 7/20/2015 | Daniel Bradbury | Director | Sell | 10,000 | $5.32 | $53,200.00 | |
| 7/8/2015 | David L Mahoney | Director | Sell | 33,828 | $5.74 | $194,172.72 | |
| 7/1/2015 | James N Wilson | Director | Sell | 10,000 | $6.06 | $60,600.00 | |
| 6/24/2015 | Daniel Bradbury | Director | Sell | 20,000 | $6.75 | $135,000.00 | |
| 6/23/2015 | Daniel Bradbury | Director | Sell | 10,000 | $6.92 | $69,200.00 | |
| 6/2/2015 | James N Wilson | Director | Sell | 10,000 | $6.13 | $61,300.00 | |
| 3/24/2015 | Patrick G Enright | Director | Sell | 1,089,745 | $5.75 | $6,266,033.75 | |
| 3/19/2015 | Joseph C Cook Jr | Director | Sell | 77,200 | $5.22 | $402,984.00 | |
| 6/11/2014 | G Leonard Baker Jr | Director | Buy | 103,386 | $2.32 | $239,855.52 | |
| 5/13/2014 | Joseph Cook, Jr. | Director | Buy | 100,000 | $1.84 | $184,000.00 | |
| 5/12/2014 | Daniel Bradbury | Director | Buy | 138,925 | $1.80 | $250,065.00 | |
| 5/9/2014 | G Leonard Baker, Jr. | Director | Buy | 100,000 | $1.84 | $184,000.00 | |
| 5/2/2014 | Longitude Venture Partners L.P | Director | Sell | 250,000 | $4.11 | $1,027,500.00 | |
| 4/1/2014 | Patrick Enright | Director | Sell | 250,000 | $4.28 | $1,070,000.00 | |
| 3/7/2014 | Longitude Venture Partners L.P | Director | Sell | 250,000 | $4.00 | $1,000,000.00 | |
| 3/14/2013 | Joseph L Turner | Director | Buy | 10,000 | $2.01 | $20,100.00 | |
| 12/5/2012 | G Leonard Baker Jr | Director | Buy | 87,131 | $1.46 | $127,211.26 | |
| 11/23/2012 | Daniel Bradbury | Director | Buy | 179,000 | $1.39 | $248,810.00 | |
| 11/7/2012 | G Leonard Baker Jr | Director | Buy | 300,000 | $1.83 | $549,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Latest Headlines for Corcept Therapeutics Incorporated (NASDAQ:CORT)
| Source: |
|
| Date | Headline |
|---|
 | Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference ... - Nasdaq
www.nasdaq.com - July 25 at 5:22 PM |
 | Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
finance.yahoo.com - July 25 at 5:22 PM |
 | Corcept Therapeutics Incorporated (CORT) to Release Earnings on Monday
www.americanbankingnews.com - July 24 at 8:41 AM |
| Corcept Therapeutics Incorporated (CORT) Upgraded to "Strong-Buy" at Zacks Investment Research
www.americanbankingnews.com - July 23 at 11:50 PM |
| David L. Mahoney Sells 6,091 Shares of Corcept Therapeutics Incorporated (CORT) Stock
www.americanbankingnews.com - July 21 at 7:51 PM |
| Corcept Therapeutics Incorporated (CORT) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 21 at 6:50 PM |
| Corcept Therapeutics Incorporated (CORT) Director Sells $287,575.00 in Stock
www.americanbankingnews.com - July 20 at 10:24 PM |
 | Is It Too Late to Get In on This Millionaire-Maker Stock?
www.fool.com - July 16 at 6:42 AM |
| David L. Mahoney Sells 6,994 Shares of Corcept Therapeutics Incorporated (CORT) Stock
www.americanbankingnews.com - July 14 at 8:46 PM |
| Corcept Therapeutics Incorporated (NASDAQ:CORT) Director David L. Mahoney Sells 6,510 Shares
www.americanbankingnews.com - July 14 at 8:46 PM |
 | Corcept Therapeutics Focuses on Korlym's Label Expansion
www.zacks.com - July 13 at 6:31 PM |
| Corcept Therapeutics Focuses on Korlym's Label Expansion
finance.yahoo.com - July 13 at 6:30 PM |
| ETFs with exposure to Corcept Therapeutics, Inc. : July 12, 2017
finance.yahoo.com - July 12 at 6:06 PM |
| Corcept Therapeutics Incorporated (NASDAQ:CORT) Upgraded at Zacks Investment Research
www.americanbankingnews.com - July 11 at 8:28 PM |
| Zacks Investment Research Lowers Corcept Therapeutics Incorporated (NASDAQ:CORT) to Sell
www.americanbankingnews.com - July 4 at 2:06 PM |
| Why is Corcept's Stock Up More Than 60% So Far This Year?
www.zacks.com - July 4 at 3:26 AM |
| Why is Corcept's Stock Up More Than 60% So Far This Year?
finance.yahoo.com - July 3 at 5:22 PM |
| ETFs with exposure to Corcept Therapeutics, Inc. : June 30, 2017
finance.yahoo.com - June 30 at 5:32 PM |
| Corcept Therapeutics Incorporated (CORT) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - June 26 at 8:42 PM |
| Corcept Therapeutics Incorporated in 3 Charts - Motley Fool
www.fool.com - June 26 at 5:14 PM |
| Corcept Therapeutics Incorporated in 3 Charts
www.fool.com - June 26 at 8:47 AM |
| Corcept Therapeutics Incorporated (CORT) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - June 24 at 7:58 PM |
| ETFs with exposure to Corcept Therapeutics, Inc. : June 19, 2017
finance.yahoo.com - June 19 at 7:12 PM |
| Corcept Therapeutics, Inc. :CORT-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 5:13 PM |
| Corcept Therapeutics Incorporated (CORT) Lowered to Hold at BidaskClub
www.americanbankingnews.com - June 15 at 6:58 PM |
| Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : June 15, 2017
finance.yahoo.com - June 15 at 6:17 PM |
| Corcept Therapeutics Incorporated (CORT) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 30 at 6:34 PM |
 | Research Reports Initiation on Biotech Stocks -- Corcept Therapeutics, Curis, OvaScience, and Vanda Pharma
www.marketwatch.com - May 30 at 11:59 AM |
| Corcept Therapeutics Incorporated (CORT) Upgraded at TheStreet
www.americanbankingnews.com - May 25 at 2:42 PM |
| Pharma Stock With Triple-Digit Growth Forming Blotchy Base
finance.yahoo.com - May 24 at 12:40 PM |
| Corcept Therapeutics Incorporated (CORT)
finance.yahoo.com - May 19 at 8:37 AM |
| ETFs with exposure to Corcept Therapeutics, Inc. : May 18, 2017
finance.yahoo.com - May 18 at 4:21 PM |
| Corcept Therapeutics Incorporated (CORT) Given a $18.00 Price Target at Piper Jaffray Companies
www.americanbankingnews.com - May 15 at 2:34 PM |
| Blog Coverage: Synthetic Biologics Wins Breakthrough Therapy Designation for its Clostridium Difficile Infection Candidate
finance.yahoo.com - May 12 at 4:57 PM |
| Corcept Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CORT-US : May 10, 2017
finance.yahoo.com - May 10 at 4:36 PM |
| Corcept Therapeutics Incorporated (CORT) CFO Gary Charles Robb Acquires 5,600 Shares
www.americanbankingnews.com - May 8 at 8:22 PM |
| Zacks Investment Research Downgrades Corcept Therapeutics Incorporated (CORT) to Hold
www.americanbankingnews.com - May 8 at 4:16 PM |
| Corcept Therapeutics Incorporated (CORT) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 5 at 11:38 AM |
| Corcept Therapeutics Announces Presentations on Mifepristone for the Treatment of Patients with Hypercortisolism at the American Association of Clinical Endocrinologists 26th Annual Congress
finance.yahoo.com - May 4 at 4:34 PM |
| TheStreet Downgrades Corcept Therapeutics Incorporated (CORT) to C+
www.americanbankingnews.com - May 3 at 5:56 PM |
| Edited Transcript of CORT earnings conference call or presentation 1-May-17 9:00pm GMT
finance.yahoo.com - May 3 at 4:24 PM |
| Corcept Therapeutics Announces First Quarter 2017 Financial ... - Yahoo Finance
finance.yahoo.com - May 3 at 8:43 AM |
| Favorable News Coverage Somewhat Likely to Affect Corcept Therapeutics (CORT) Share Price
www.americanbankingnews.com - May 3 at 1:01 AM |
| Corcept posts 1Q profit
finance.yahoo.com - May 2 at 7:34 PM |
| Corcept Therapeutics Incorporated (CORT) Releases Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 2 at 1:03 PM |
| Investor Network: Corcept Therapeutics Incorporated. to Host Earnings Call
finance.yahoo.com - May 1 at 4:24 PM |
| Corcept Therapeutics Announces First Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update
finance.yahoo.com - May 1 at 4:24 PM |
| Corcept Therapeutics Incorporated (CORT) Short Interest Update
www.americanbankingnews.com - April 29 at 11:56 PM |
| Corcept Therapeutics (CORT) Receiving Somewhat Negative Press Coverage, Report Finds
www.americanbankingnews.com - April 29 at 8:28 AM |
| Corcept Therapeutics Incorporated (CORT) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 29 at 1:17 AM |
Corcept Therapeutics Incorporated (CORT) Chart for Wednesday, July, 26, 2017
